褪黑素對子宮內膜癌的影響_West China Medical Journal

Authors：

 陳華芳 ,  胡雅毅 , 楊沛

四川大學華西第二醫院婦產科（成都 610041）;

Corresponding?author：

胡雅毅, Email: yayi.hu@163.com

Keywords：

褪黑素; 子宮內膜癌; 病因機制; 抗腫瘤; 流行病學

DOI：

10.7507/1002-0179.20150274

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

子宮內膜癌是女性生殖道三大惡性腫瘤之一，病因迄今尚不明確，可能的危險因素有：肥胖、高血壓、糖尿病、外源性雌激素的增加、高雌激素導致的初潮提前和絕經推后、卵巢腫瘤等。褪黑素作為一種主要由松果體分泌的神經內分泌激素，有調節睡眠/覺醒周期、免疫調節、細胞凋亡調節及抗氧化等多種生理功能。由于其抗氧化、免疫刺激、誘導凋亡等特性，在許多腫瘤的抑制和治療上有一定效果。同時還具有調節血脂、血壓、血糖，調節卵巢功能，抑制子宮內膜增生和子宮內膜癌細胞增殖，恢復子宮內膜等作用。因此，褪黑素水平的降低會增加子宮內膜癌的發病風險，且對其治療有一定作用。現就褪黑素對子宮內膜癌的影響作一綜述。

Citation： 陳華芳, 胡雅毅, 楊沛. 褪黑素對子宮內膜癌的影響. West China Medical Journal, 2015, 30(5): 959-962. doi: 10.7507/1002-0179.20150274 Copy

1.	張燕, 相成, 李立新, 等. 褪黑素的器官保護作用研究現狀[J]. 臨床合理用藥雜志, 2013, 6(5):179-180.
2.	Srinivasan V, Pandi-Perumal SR, Brzezinski A, et al. Melatonin, immune function and cancer[J]. Recent Pat Endocr Metab Immune Drug Discov, 2011, 5(2):109-123.
3.	Luchetti F, Canonico B, Betti M, et al. Melatonin signaling and cell protection function[J]. FASEB J, 2010, 24(10):3603-3624.
4.	Mills E, Wu P, Seely D, et al. Melatonin in the treatment of cancer:a systematic review of randomized controlled trials and meta-analysis[J].J Pineal Res, 2005, 39(4):360-366.
5.	Neri B, de Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients[J]. Anticancer Res, 1998, 18(2B):1329-1332.
6.	李伶俐, 林漢華, 陳曉娟, 等. 外源性褪黑素水平對雌性性早熟大鼠的影響[J]. 實用兒科臨床雜志, 2007, 22(20):1539-1541.
7.	許建寧, 許建萍, 李金福, 等. 褪黑激素對大鼠泌乳素瘤細胞生長影響的研究[J]. 中國醫藥工業雜志, 2003, 34(6):283-284, 301.
8.	Cos S, Sánchez-Barceló EJ. Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation[J]. Cancer Lett, 1994, 85(1):105-109.
9.	Vijayalaxmi, Reiter RJ, Meltz ML. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage[J]. Mutal Res, 1995, 346(1):23-31.
10.	Conti A, Maestroni GJ. The clinical neuroimmunotherapeutic role of melatonin in oncology[J]. J Pineal Res, 1995, 19(3):103-110.
11.	Srinivasan V, Spence DW, Pandi-Perumal SR, et al. Therapeutic actions of melatonin in cancer:possible mechanisms[J]. Integr Cancer Ther, 2008, 7(3):189-203.
12.	林仲秋, 王麗娟. 子宮內膜癌相關危險因素及預防[J]. 中國實用婦科與產科雜志, 2010, 26(9):657-660.
13.	Ali AT. Risk factors for endometrial cancer[J]. Ceska Gynekol, 2013, 78(5):48-59.
14.	付景冉, 盧麗娜, 余莉萍. 脂聯素和2型糖尿病與子宮內膜癌相關性的研究進展[J]. 廣東醫學, 2012, 33(12):1841-1842.
15.	Sewerynek E. Melatonin and the cardiovascular system[J]. Neuro Endocrinol Lett, 2002, 23(Suppl 1):79-83.
16.	Giortea R, Costin N, Bracicu I, et al. Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats[J]. Anticancer Res, 2011, 31(8):2637-2643.
17.	Koziróg M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome[J]. J Pineal Res, 2011, 50(3):261-266.
18.	Sailaja Devi MM, Suresh Y, Das. Preservation of the antioxidant status in chemically-induced diabetes mellitus by melatonin[J]. J Pineal Res, 2000, 29(2):108-115.
19.	Fabris N, Mocchegiani E, Provinciali M, et al. Plasticity of neuroendocrine-thymus interactions during aging[J]. Exp Gerontol, 1997, 32(4/5):415-429.
20.	Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation[J]. Best Pract Res Clin Endocrinol Metab, 2010, 24(5):829-841.
21.	Paulis L, Pechanova O, Zicha J, et al. Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension[J]. J Pineal Res, 2010, 48(2):102-108.
22.	Koziróg M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profil, and parameters of oxidative stress in patients with metabolic syndrome[J]. J Pineal Res, 2011, 50(3):261-266.
23.	Waldhauser F, Boepple PA, Schemper M, et al. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children[J]. J Clin Endocrinol Metab, 1991, 73(4):793-796.
24.	Tamura H, Nakamura Y, Korkmaz A, et al. Melatonin and the ovary:physiological and pathophysiological implications[J]. Fertil Steril, 2009, 92(1):328-343.
25.	Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, et al. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model:influence of long-term melatonin treatment[J]. PLoS One, 2013, 8(12):e81676.
26.	尼佳樂, 紀春華, 陳歡歡, 等. 褪黑素對小鼠子宮內膜發育的影響[J]. 新鄉醫學院學報, 2010, 27(1):18-20.
27.	Ciortea R, Costin N, Braicu I, et al. Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats[J]. Anticancer Res, 2011, 31(8):2637-2643.
28.	Bellipanni G, Bianchi P, Pierpaoli W, et al. Effects of melatonin in perimenopausal and menopausal women:a randomized and placebo controlled study[J]. Exp Gerontol, 2001, 36(2):297-310.
29.	辜榮飛, 鄒俊杰, 劉志民, 等. 褪黑素對性激素及排卵的調節作用研究[J]. 解放軍醫學雜志, 2003, 28(3):236-237.
30.	Grin W, Grünberger W. A significant correlation between melatonin deficiency and endometrial cancer[J]. Gynecol Obstet Invest, 1998, 45(1):62-65.
31.	Stanosz S, Von Mach-Szczypiński J, Sieja K, et al. Micronized estradiol and progesterone therapy in primary, preinvasive endometrial cancer (1a/G1) in young women with polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2014, 99(12):E2472-E2476.
32.	Watanabe M, Kobayashi Y, Takahashi N, et al. Expression of melatonin receptor (MT₁) and interaction between melatonin and estrogen in endometrial cancer cell line[J]. J Obstet Gynaecol Res, 2008, 34(4):567-573.
33.	Nishida M. The Ishikawa cells from birth to the present[J]. Hum Cell, 2002, 15(3):104-117.
34.	Kobayashi Y, Itoh MT, Kondo H. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer[J]. J Pineal Res, 2003, 35(2):71-74.
35.	Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer[J]. Cancer Res, 2007, 67(21):10618-10622.
36.	Lissoni P, Malugani F, Bukovec R, et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients[J]. Neuro Endocrinol Lett, 2003, 24(1/2):83-85.

1. 張燕, 相成, 李立新, 等. 褪黑素的器官保護作用研究現狀[J]. 臨床合理用藥雜志, 2013, 6(5):179-180.
2. Srinivasan V, Pandi-Perumal SR, Brzezinski A, et al. Melatonin, immune function and cancer[J]. Recent Pat Endocr Metab Immune Drug Discov, 2011, 5(2):109-123.
3. Luchetti F, Canonico B, Betti M, et al. Melatonin signaling and cell protection function[J]. FASEB J, 2010, 24(10):3603-3624.
4. Mills E, Wu P, Seely D, et al. Melatonin in the treatment of cancer:a systematic review of randomized controlled trials and meta-analysis[J].J Pineal Res, 2005, 39(4):360-366.
5. Neri B, de Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients[J]. Anticancer Res, 1998, 18(2B):1329-1332.
6. 李伶俐, 林漢華, 陳曉娟, 等. 外源性褪黑素水平對雌性性早熟大鼠的影響[J]. 實用兒科臨床雜志, 2007, 22(20):1539-1541.
7. 許建寧, 許建萍, 李金福, 等. 褪黑激素對大鼠泌乳素瘤細胞生長影響的研究[J]. 中國醫藥工業雜志, 2003, 34(6):283-284, 301.
8. Cos S, Sánchez-Barceló EJ. Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation[J]. Cancer Lett, 1994, 85(1):105-109.
9. Vijayalaxmi, Reiter RJ, Meltz ML. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage[J]. Mutal Res, 1995, 346(1):23-31.
10. Conti A, Maestroni GJ. The clinical neuroimmunotherapeutic role of melatonin in oncology[J]. J Pineal Res, 1995, 19(3):103-110.
11. Srinivasan V, Spence DW, Pandi-Perumal SR, et al. Therapeutic actions of melatonin in cancer:possible mechanisms[J]. Integr Cancer Ther, 2008, 7(3):189-203.
12. 林仲秋, 王麗娟. 子宮內膜癌相關危險因素及預防[J]. 中國實用婦科與產科雜志, 2010, 26(9):657-660.
13. Ali AT. Risk factors for endometrial cancer[J]. Ceska Gynekol, 2013, 78(5):48-59.
14. 付景冉, 盧麗娜, 余莉萍. 脂聯素和2型糖尿病與子宮內膜癌相關性的研究進展[J]. 廣東醫學, 2012, 33(12):1841-1842.
15. Sewerynek E. Melatonin and the cardiovascular system[J]. Neuro Endocrinol Lett, 2002, 23(Suppl 1):79-83.
16. Giortea R, Costin N, Bracicu I, et al. Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats[J]. Anticancer Res, 2011, 31(8):2637-2643.
17. Koziróg M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome[J]. J Pineal Res, 2011, 50(3):261-266.
18. Sailaja Devi MM, Suresh Y, Das. Preservation of the antioxidant status in chemically-induced diabetes mellitus by melatonin[J]. J Pineal Res, 2000, 29(2):108-115.
19. Fabris N, Mocchegiani E, Provinciali M, et al. Plasticity of neuroendocrine-thymus interactions during aging[J]. Exp Gerontol, 1997, 32(4/5):415-429.
20. Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation[J]. Best Pract Res Clin Endocrinol Metab, 2010, 24(5):829-841.
21. Paulis L, Pechanova O, Zicha J, et al. Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension[J]. J Pineal Res, 2010, 48(2):102-108.
22. Koziróg M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profil, and parameters of oxidative stress in patients with metabolic syndrome[J]. J Pineal Res, 2011, 50(3):261-266.
23. Waldhauser F, Boepple PA, Schemper M, et al. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children[J]. J Clin Endocrinol Metab, 1991, 73(4):793-796.
24. Tamura H, Nakamura Y, Korkmaz A, et al. Melatonin and the ovary:physiological and pathophysiological implications[J]. Fertil Steril, 2009, 92(1):328-343.
25. Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, et al. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model:influence of long-term melatonin treatment[J]. PLoS One, 2013, 8(12):e81676.
26. 尼佳樂, 紀春華, 陳歡歡, 等. 褪黑素對小鼠子宮內膜發育的影響[J]. 新鄉醫學院學報, 2010, 27(1):18-20.
27. Ciortea R, Costin N, Braicu I, et al. Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats[J]. Anticancer Res, 2011, 31(8):2637-2643.
28. Bellipanni G, Bianchi P, Pierpaoli W, et al. Effects of melatonin in perimenopausal and menopausal women:a randomized and placebo controlled study[J]. Exp Gerontol, 2001, 36(2):297-310.
29. 辜榮飛, 鄒俊杰, 劉志民, 等. 褪黑素對性激素及排卵的調節作用研究[J]. 解放軍醫學雜志, 2003, 28(3):236-237.
30. Grin W, Grünberger W. A significant correlation between melatonin deficiency and endometrial cancer[J]. Gynecol Obstet Invest, 1998, 45(1):62-65.
31. Stanosz S, Von Mach-Szczypiński J, Sieja K, et al. Micronized estradiol and progesterone therapy in primary, preinvasive endometrial cancer (1a/G1) in young women with polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2014, 99(12):E2472-E2476.
32. Watanabe M, Kobayashi Y, Takahashi N, et al. Expression of melatonin receptor (MT₁) and interaction between melatonin and estrogen in endometrial cancer cell line[J]. J Obstet Gynaecol Res, 2008, 34(4):567-573.
33. Nishida M. The Ishikawa cells from birth to the present[J]. Hum Cell, 2002, 15(3):104-117.
34. Kobayashi Y, Itoh MT, Kondo H. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer[J]. J Pineal Res, 2003, 35(2):71-74.
35. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer[J]. Cancer Res, 2007, 67(21):10618-10622.
36. Lissoni P, Malugani F, Bukovec R, et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients[J]. Neuro Endocrinol Lett, 2003, 24(1/2):83-85.

Previous Article
國內外結核病診療指南中關于抗結核藥物相互作用管理的分析
Next Article
子癇前期患者麻醉管理新進展

West China Medical Journal

褪黑素對子宮內膜癌的影響

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content